FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlzamend Neuro, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALZN
Alzamend Neuro, Inc. Stock AnalysisComprehensive stock analysis for Alzamend Neuro, Inc. (ALZN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALZN
ALZN
Alzamend Neuro, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALZN
  1. Home
  2. Stocks
  3. Alzamend Neuro, Inc.

Alzamend Neuro, Inc.

🇺🇸ALZN•NASDAQ

Alzamend Neuro, Inc.

🇺🇸ALZN•NASDAQ
Market cap
$3.74M

Your view on ALZN

Mkt Cap
$3.74M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Alzamend Neuro, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Stephan Jackman
Headquarters
3500 Lenox Road NE, Atlanta, GA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Stephan Jackman
Headquarters
3500 Lenox Road NE, Atlanta, GA, US
Description

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Alzamend Neuro, Inc.. Starting points for Alzamend Neuro, Inc.: EPS -$2.03, beta 0.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Alzamend Neuro, Inc.. Trailing twelve-month EPS for Alzamend Neuro, Inc. stands at -$2.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Alzamend Neuro, Inc.. Alzamend Neuro, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALZN12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
REPCFRepliCel Life Sciences Inc.HealthcareOTC$7,358
REPLReplimune Group, Inc.HealthcareNASDAQ$1.8B
REVBRevelation Biosciences, Inc.HealthcareNASDAQ$2.0M
REVBWRevelation Biosciences, Inc.HealthcareNASDAQ$27,251
RGBPRegen BioPharma, Inc.HealthcareOTC$37,866
RGBPPRegen BioPharma, Inc.HealthcareOTC$89,893
RGINRegenicin, Inc.HealthcareOTC$15,348
RGNXREGENXBIO Inc.HealthcareNASDAQ$473.4M
RGRXRegeneRx Biopharmaceuticals, Inc.HealthcareOTC$449
RIGLRigel Pharmaceuticals, Inc.HealthcareNASDAQ$754.9M
RLAYRelay Therapeutics, Inc.HealthcareNASDAQ$3.6B
RLFTFRelief Therapeutics Holding AGHealthcareOTC$11.9M
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Alzamend Neuro, Inc., and how their positions are changing. At a $3.7M market value, institutional positions materially move Alzamend Neuro, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Alzamend Neuro, Inc. executives and directors. Shares of Alzamend Neuro, Inc. have traded between $2.06 and $12.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Alzamend Neuro, Inc.. Coverage tracks Alzamend Neuro, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Alzamend Neuro, Inc.

ALZN AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1